Tag: Prescription Drugs
SARS-CoV-2 mAbs Continued to Be Used After FDA Deauthorization
More than 158,000 doses of bamlanivimab-etesevimab and casirivimab-imdevimab were used after deauthorization on Jan. 24, 2022
Polypill Cuts Cardiovascular Event Risk in Seniors With Recent MI
Polypill comprising aspirin, ramipril, atorvastatin effective for secondary prevention of cardiovascular disease in older adults
Dapagliflozin Cuts CV Risk in Heart Failure With Preserved LVEF
Risk reduced for primary outcome of worsening heart failure or cardiovascular death
Acetazolamide Helps Treat Volume Overload in Heart Failure
Rate of successful decongestion higher with addition of acetazolamide to loop diuretic in patients with acute decompensated heart failure
Tecovirimat Well Tolerated for Treatment of Monkeypox
By day 21, 23 of 25 patients had resolution of lesions and pain; none of the patients discontinued treatment
Industry Payments to Prescribers May Influence Choice of Eye Drops
Positive association seen between amount of transfers of value and frequency of prescribing branded prostaglandin analog eye drops
Rates of Severe COVID-19 Lower With Nirmatrelvir in ≥65s
Rate of hospitalization due to COVID-19 and death reduced for treated versus untreated patients among those aged 65 years and older
Olokizumab Tops Placebo for RA Patients Receiving Methotrexate
Olokizumab superior to placebo and noninferior to adalimumab in producing ACR20 response at 12 weeks
ACOG Develops Consensus on Medical Menstrual Suppression
Guidance emphasizes role of hormonal therapy and should be accompanied by counseling, including discussions of effectiveness of therapy
Out-of-Pocket Costs for Naloxone Up for Uninsured Patients
For 2018 compared with 2014, mean out-of-pocket cost of naloxone increased by 506 percent among uninsured patients
